Targeting Spike Proteins Research Articles

Quantitative SARS-CoV-2 Alpha Variant B.1.1.7 Tracking in Wastewater by Allele-Specific RT-qPCR

The critical need for surveillance of SARS-CoV-2 variants of concern has prompted the development of methods that can track variants in wastewater. Here, we develop and present an open-source method based on allele-specific RT-qPCR (AS RT-qPCR) that detects and quantifies the B.1.1.7 variant, targeting spike protein mutations at three independent genomic loci that are highly predictive of B.1.1.7 (HV69/70del, Y144del, and A570D). Our assays can reliably detect and quantify low levels of B.1.1.7 with low cross-reactivity, and at variant proportions down to 1% in a background of mixed SARS-CoV-2. Applying our method to wastewater samples from the United States, we track the occurrence of B.1.1.7 over time in 19 communities. AS RT-qPCR results align with clinical trends, and summation of B.1.1.7 and wild-type sequences quantified by our assays matches SARS-CoV-2 levels indicated by the U.S. CDC N1 and N2 assays. This work paves the way for AS RT-qPCR as a method for rapid inexpensive surveillance of SARS-CoV-2 variants in wastewater.

SARS‐CoV‐2 Spike Proteins: A Key Target for COVID‐19 Therapeutics Development

The spike proteins that crown SARS‐CoV‐2, the novel coronavirus behind the nearly 2 million COVID‐19 deaths this year, may be the key to stopping the infectious disease firmly in its tracks. By recognizing and attaching to human cells, these spike proteins spearhead the process of SARS‐CoV‐2 infection in the body. Thus, understanding their architecture and mechanics is critical to pinpointing the vulnerabilities of this coronavirus and guiding therapeutic development. To that end, here we present a review of the latest discoveries in the spike proteins’ structure and function alongside a physical model of the spike protein, highlighting features of clinical interest in antibody, small‐molecule drug, and vaccine development.The spike protein is comprised of two functional domains. The outer S1 domain includes the receptor binding domain, which recognizes and binds to an angiotensin‐converting enzyme 2 (ACE2) receptor on the surface of a lung, heart, kidney, or intestinal cell. Then, facilitated by the highly flexible inner S2 domain, the spike protein folds in on itself and fuses the viral envelope with the plasma membrane of the human cell. In doing so, the spike protein opens the doors for SARS‐CoV‐2 to release its viral genome inside the cell. Because spike proteins are glycoproteins, meaning their ectodomain is covered with sugar chains, the virus can evade the detection of the immune system and spread quickly throughout vital organsThe spike protein's position on the outer surface of SARS‐CoV‐2 and its critical role in the virus's function makes it one of the most promising targets for a coronavirus therapeutic. One novel approach to targeting spike proteins is the design of Anti‐S1 antibodies, which disarm the virus's ability to bind to the cell by attaching to the S1 subunit. The current challenge to antibody development is the flexibility of the S1 domain, which makes fusion highly effective. Further research is needed to stabilize the spike protein and maximize the efficacy of antibodies in inhibiting the virus's function. Another intriguing approach to coronavirus therapeutics is small‐molecule drug development. When linoleic acid (LA), an essential fatty acid molecule that maintains lung cell membranes, nestles into a newly discovered druggable pocket of the spike protein, the spike protein is locked into a less flexible, less infectious form. This new pocket is a putative binding site for even more potent small‐molecule inhibitors, which may be able to trap the spike protein in a completely non‐infectious form. With each new discovery surrounding the structure of the spike proteins at the heart of the COVID‐19 pandemic, we advance one step closer to developing novel therapeutics that trap SARS‐CoV‐2 in a virtually non‐infectious state.

Biological source and virtual screening of phytochemicals present in important ayurvedic plant, Sesbania sesban targeting spike proteins of SARS CoV2 for treatment of COVID 19

Biological source and virtual screening of phytochemicals present in important ayurvedic plant, Sesbania sesban targeting spike proteins of SARS CoV2 for treatment of COVID 19

Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays Authorized for Emergency Use

A total of 1,200 serum samples that were tested for SARS-CoV-2 IgG antibody using the Abbott Architect immunoassay targeting the nucleocapsid protein were run in 3 SARS-CoV-2 IgG immunoassays targeting spike proteins (DiaSorin Liaison, Ortho Vitros, and Euroimmun). Consensus-positive and consensus-negative interpretations were defined as qualitative agreement in at least 3 of the 4 assays. Agreement of the 4 individual assays with a consensus-negative interpretation (n = 610) ranged from 96.7% to 100%, and agreement with a consensus-positive interpretation (n = 584) ranged from 94.3% to 100%. Laboratory-developed inhibition assays were utilized to evaluate 49 consensus-negative samples that were positive in only one assay; true-positive reactivity was confirmed in only 2 of these 49 (4%) samples. These findings demonstrate very high levels of agreement among 4 SARS-CoV-2 IgG assays authorized for emergency use, regardless of antigen target or assay format. Although false-positive reactivity was identified, its occurrence was rare (no more than 1.7% of samples for a given assay).

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein

The recent outbreak of Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) infection has led to more than 800 laboratory-confirmed MERS cases with a high case fatality rate (∼35%), posing a serious threat to global public health and calling for the development of effective and safe therapeutic and prophylactic strategies to treat and prevent MERS-CoV infection. Here we discuss the most recent studies on the structure of the MERS-CoV spike protein and its role in virus binding and entry, and the development of MERS-CoV entry/fusion inhibitors targeting the S1 subunit, particularly the receptor-binding domain (RBD), and the S2 subunit, especially the HR1 region, of the MERS-CoV spike protein. We then look ahead to future applications of these viral entry/fusion inhibitors, either alone or in combination with specific and nonspecific MERS-CoV replication inhibitors, for the treatment and prevention of MERS-CoV infection.

Macrophage-Mediated Optic Neuritis Induced by Retrograde Axonal Transport of Spike Gene Recombinant Mouse Hepatitis Virus

After intracranial inoculation, neurovirulent mouse hepatitis virus (MHV) strains induce acute inflammation, demyelination, and axonal loss in the central nervous system. Prior studies using recombinant MHV strains that differ only in the spike gene, which encodes a glycoprotein involved in virus-host cell attachment, demonstrated that spike mediates anterograde axonal transport of virus to the spinal cord. A demyelinating MHV strain induces optic neuritis, but whether this is due to the retrograde axonal transport of viral particles to the retina or due to traumatic disruption of retinal ganglion cell axons during intracranial inoculation is not known. Using recombinant isogenic MHV strains, we examined the ability of recombinant MHV to induce optic neuritis by retrograde spread from the brain through the optic nerve into the eye after intracranial inoculation. Recombinant demyelinating MHV induced macrophage infiltration of optic nerves, demyelination, and axonal loss, whereas optic neuritis and axonal injury were minimal in mice infected with the nondemyelinating MHV strain that differs in the spike gene. Thus, optic neuritis was dependent on a spike glycoprotein-mediated mechanism of viral antigen transport along retinal ganglion cell axons. These data indicate that MHV spreads by retrograde axonal transport to the eye and that targeting spike protein interactions with axonal transport machinery is a potential therapeutic strategy for central nervous system viral infections and associated diseases.

Multivalent DNA Vaccine Enhanced Protection Efficacy against Infectious Bronchitis Virus in Chickens

For efficacious DNA vaccine development against infectious bronchitis virus (IBV), the immunogenicity of a multivalent DNA vaccine was evaluated. Three expression plasmids each targeting spike protein (S1), nucleocapsid protein (N), and membrane protein (M) of IBV were prepared. Chickens were immunized with either individual plasmids (monovalent) or with a combination of all plasmids (multivalent). Immunization with the multivalent DNA vaccine induced synergistic augmentation of humoral and cellular responses in comparison with the individual vaccines, and provided up to 85% immune protection. Thus the multivalent DNA vaccine represents an innovative approach for enhancing DNA vaccine potency, and has potential clinical application for vaccination against IBV.